The drug was developed by the Novosibirsk center “Vector”, subordinate to Rospotrebnadzor. Vaccine creators earlier spokethat it will be almost indistinguishable from the original EpiVacCorona, but it will be easier and faster to produce.
Head of “Vector” Rinat Maksyutov explainedthat vaccines differ only in technological features – the development of a new drug is necessary to enter large-scale production. “EpiVacCorona-N” is also created on the basis of peptide antigens in the form of a suspension. You will need to enter it three times with an interval of 21 and 60 days.
The drug “EpiVacCorona” was registered in Russia in October last year. Clinical trials of the drug began in December, and the vaccine entered January 1st. They began to vaccinate her all comers this spring. According to Rospotrebnadzor, the research results showed 100% effectiveness of the vaccine.
In March, volunteers who tested EpiVacCorona asked The Ministry of Health will publish the results of the experiment and organize a study independent of Rospotrebnadzor. A month later at the ministry answeredthat the drug was registered in the prescribed manner, and its effectiveness and safety were confirmed, despite the fact that many of those who were vaccinated complained that they did not produce neutralizing antibodies.